These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
3. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related]
5. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
7. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma]. Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743 [TBL] [Abstract][Full Text] [Related]
8. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
9. Treatment paradigms for the newly diagnosed patient with multiple myeloma. Greipp P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097 [TBL] [Abstract][Full Text] [Related]
10. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma. Manochakian R; Miller KC; Chanan-Khan AA Oncologist; 2007 Aug; 12(8):978-90. PubMed ID: 17766658 [TBL] [Abstract][Full Text] [Related]
12. Integrating novel therapies in the transplant paradigm. Harousseau JL Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167 [TBL] [Abstract][Full Text] [Related]
13. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
14. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related]
16. Update on recent developments for patients with newly diagnosed multiple myeloma. Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878 [TBL] [Abstract][Full Text] [Related]
17. Management of older patients with multiple myeloma. Gay F; Palumbo A Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387 [TBL] [Abstract][Full Text] [Related]
18. Emerging role of novel combinations for induction therapy in multiple myeloma. Voorhees PM; Orlowski RZ Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768 [TBL] [Abstract][Full Text] [Related]
19. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ; Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257 [TBL] [Abstract][Full Text] [Related]
20. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network. Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ; Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]